Thursday September 20, 2018 16:30

Heathcare Press Release : 20 Aug 2018

Singapore#s first clinical trial approval for T cell engineered (TCR) immunotherapy for treatment Heathcare—20 Aug 18

Lion TCR Pte. Ltd., a Singapore-based Biotech company receives approval from Health Sciences Authority (HSA), Singapore, for its Phase I/II multicentre clinical study of its product candidate (LioCyx(TM)) for treatment of relapsed liver cancer post-liver